This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Effectiveness results
The results are presented for the clopidogrel group versus the placebo group.
The rate of composite event was 8.5% versus 11.5%, (p=0.02).
The relative risk reduction was 26.9% (95% confidence interval, CI: 3.9 to 44.4).
The rate of cardiovascular death was 1.7% versus 2.3%, (p=0.45).
The rate of nonfatal MI was 6.6% versus 8.5%, (p=0.13).
The rate of stroke was 0.9% versus 1.1%, (p=0.68).
The rate of major bleeding was 8.8% versus 6.7%, (p=0.07).
The rate of minor bleeding was 5.3% compared with 5.6%, (p = 0.84).
Clinical conclusions
The effectiveness analysis showed that clopidogrel was associated with fewer fatal and nonfatal cardiovascular events. There were, however, more incidences of major bleeding among those receiving clopidogrel.
Measure of benefits used in the economic analysis
The outcome measure used was the number of life-years gained (LYG). This was estimated from two independent sources, the Framingham Heart Study and the Saskatchewan Health database. These sources provided estimates of lifeyears lost due to events (death, MI and stroke). The life-years lost were calculated by subtracting the mean survival given observed events in the trial, from the survival expected with no events. Mean survival was calculated by integrating the survival curves, adjusted for various patient characteristics, including experience of specific ischemic events. For patients who experienced multiple events of different types during the trial, lost life expectancy was estimated assuming a hierarchy of death, stroke and MI. It was further assumed that clopidogrel would be stopped at the end of the trial, thus there would be no reduction (or increase) in nonfatal events between the two arms. An annual discount rate of 3% was applied to future LYG.
Direct costs
The costs included in the analysis were the direct medical care costs for hospitalisation and the cost of clopidogrel and aspirin. The direct costs associated with ambulatory care and outpatient visits were not included since there was no information available from the CREDO trial. The impact of bleeding on cost was derived using CURE trial data as this was not available in the CREDO trial dataset. The cost of other medication was not included as medication use other than the study drug was not found to differ between the two groups. Resource use was collectively prospectively within the CREDO trial. Each hospitalisation was assigned a diagnosis-related group (DRG), as used in Medicare programmes Blending the effectiveness estimates from the Framingham and Saskatchewan data results in the three costing approaches yielded similar results, with over 90% of bootstrap-derived ICERs below $18,000.
The sensitivity analysis showed that if the estimated gain in life expectancy was only half of that projected, the ICER would be $8,706 (with 95.7% of bootstrap samples less than $50,000/LYG) when using the blended costing approach and Framingham life expectancy estimates, and $6,921 (with 97.9% less than $50,000/LYG) on the basis of Saskatchewan data. If the life expectancy gain was just 20% of that projected, the ICER would be $21,766 (with 82.7% less than $50,000/LYG) on the basis of Framingham estimates and $17,302 (with 89.3% less than $50,000/LYG) on the basis of Saskatchewan estimates.
The results of other sensitivity analyses were fully presented in the paper.
Authors' conclusions
A loading strategy followed by 1 year of antiplatelet therapy with clopidogrel was highly cost-effective for patients undergoing percutaneous coronary intervention (PCI).
CRD COMMENTARY -Selection of comparators
The selection of the comparator was appropriate given the question being evaluated.
Validity of estimate of measure of effectiveness
The effectiveness data came from a prospective, randomised clinical trial, which was appropriate for the study question. Since the study had been published already, only key characteristics of the patient sample and study design were reported in the current publication. Thus, it was difficult to assess the internal validity of the study. However, some details of the study details that were presented, such as the large sample of patients, the randomised design and the baseline comparability, suggest that the clinical information is likely to be robust. However, to fully evaluate the validity of the clinical trial the reader will need to refer to the parent clinical paper (Steinhubl et al. 2002) .
Validity of estimate of measure of benefit
The summary benefit measure (i.e. LYG) was appropriate. The authors stated that utility estimates were not available, thus quality-adjusted life-years (QALYs) could not be calculated directly from the patient level data. Therefore, QALYS were only discussed for illustrative purposes in the sensitivity analysis and all values were based on 'what if' type assumptions.
Validity of estimate of costs
The authors stated that a societal perspective was adopted in the study. However, since the costs were mainly derived from reimbursement rates and productivity losses were not included, the perspective of a third-party payer appears to have been used. The authors noted the lack of indirect costs as a limitation, and suggested that they would be higher among the placebo group because there were more events that could lead to more resource consumption and more time lost from work. They suggested, therefore, that not including indirect costs underestimated the cost-effectiveness of clopidogrel. Private cost estimates were also used, and blended estimates were reported together with totally private or totally public rates. The authors excluded some categories of costs because of a lack of available data and excluded others because of the lack of a statistical difference between the groups. The source of the data was reported and most resource use information came from the clinical trial, thus patient-level data were used. The price year was stated which will aid reflation exercises.
